Human PCSK9 promotes hepatic lipogenesis and atherosclerosis development via apoE- and LDLR-mediated mechanisms
Published 2016 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Human PCSK9 promotes hepatic lipogenesis and atherosclerosis development via apoE- and LDLR-mediated mechanisms
Authors
Keywords
-
Journal
CARDIOVASCULAR RESEARCH
Volume 110, Issue 2, Pages 268-278
Publisher
Oxford University Press (OUP)
Online
2016-03-16
DOI
10.1093/cvr/cvw053
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- On the function and homeostasis of PCSK9: Reciprocal interaction with LDLR and additional lipid effects
- (2015) Hagai Tavori et al. ATHEROSCLEROSIS
- Pro-protein convertase subtilisin/kexin 9 concentrations correlate with coronary artery disease atheroma burden in a Pakistani cohort with chronic chest pain
- (2015) T. A. Walton et al. INTERNATIONAL JOURNAL OF CLINICAL PRACTICE
- Local effects of human PCSK9 on the atherosclerotic lesion
- (2015) Ilaria Giunzioni et al. JOURNAL OF PATHOLOGY
- Inhibition of PCSK9 with evolocumab in homozygous familial hypercholesterolaemia (TESLA Part B): a randomised, double-blind, placebo-controlled trial
- (2015) Frederick J Raal et al. LANCET
- Efficacy and Safety of Alirocumab in Reducing Lipids and Cardiovascular Events
- (2015) Jennifer G. Robinson et al. NEW ENGLAND JOURNAL OF MEDICINE
- Efficacy and Safety of Evolocumab in Reducing Lipids and Cardiovascular Events
- (2015) Marc S. Sabatine et al. NEW ENGLAND JOURNAL OF MEDICINE
- Hepatic Overexpression of Idol Increases Circulating Protein Convertase Subtilisin/Kexin Type 9 in Mice and Hamsters via Dual Mechanisms
- (2014) Makoto Sasaki et al. ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY
- PCSK9 R46L, Lower LDL, and Cardiovascular Disease Risk in Familial Hypercholesterolemia
- (2014) Yascara Grisel Luna Saavedra et al. ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY
- Association of plasma PCSK9 levels with white blood cell count and its subsets in patients with stable coronary artery disease
- (2014) Sha Li et al. ATHEROSCLEROSIS
- Proprotein Convertase Subtilisin Kexin Type 9 Promotes Intestinal Overproduction of Triglyceride-Rich Apolipoprotein B Lipoproteins Through Both Low-Density Lipoprotein Receptor–Dependent and –Independent Mechanisms
- (2014) Shirya Rashid et al. CIRCULATION
- PCSK9
- (2014) Nabil G. Seidah et al. CIRCULATION RESEARCH
- AAV Vectors Expressing LDLR Gain-of-Function Variants Demonstrate Increased Efficacy in Mouse Models of Familial Hypercholesterolemia
- (2014) Suryanarayan Somanathan et al. CIRCULATION RESEARCH
- Plasma proprotein convertase subtilisin–kexin type 9 is predominantly related to intermediate density lipoproteins
- (2014) Arjan J. Kwakernaak et al. CLINICAL BIOCHEMISTRY
- Macrophage-derived apoESendaisuppresses atherosclerosis while causing lipoprotein glomerulopathy in hyperlipidemic mice
- (2014) Hagai Tavori et al. JOURNAL OF LIPID RESEARCH
- PCSK9 inhibition fails to alter hepatic LDLR, circulating cholesterol, and atherosclerosis in the absence of ApoE
- (2014) Brandon Ason et al. JOURNAL OF LIPID RESEARCH
- Alirocumab inhibits atherosclerosis, improves the plaque morphology, and enhances the effects of a statin
- (2014) Susan Kühnast et al. JOURNAL OF LIPID RESEARCH
- Normalization of Low-Density Lipoprotein Receptor Expression in Receptor Defective Homozygous Familial Hypercholesterolemia by Inhibition of PCSK9 With Alirocumab
- (2014) Gilles Lambert et al. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
- Anti-PCSK9 Antibody Effectively Lowers Cholesterol in Patients With Statin Intolerance
- (2014) Erik Stroes et al. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
- Anti-PCSK9 Monotherapy for Hypercholesterolemia
- (2014) Michael J. Koren et al. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
- A 52-Week Placebo-Controlled Trial of Evolocumab in Hyperlipidemia
- (2014) Dirk J. Blom et al. NEW ENGLAND JOURNAL OF MEDICINE
- PCSK9 is a critical regulator of the innate immune response and septic shock outcome
- (2014) K. R. Walley et al. Science Translational Medicine
- Beyond LDL-C lowering: Distinct molecular sphingolipids are good indicators of proprotein convertase subtilisin/kexin type 9 (PCSK9) deficiency
- (2013) Minna T. Jänis et al. ATHEROSCLEROSIS
- PCSK9 plays a significant role in cholesterol homeostasis and lipid transport in intestinal epithelial cells
- (2013) Emile Levy et al. ATHEROSCLEROSIS
- Activation of mTOR modulates SREBP-2 to induce foam cell formation through increased retinoblastoma protein phosphorylation
- (2013) K. L. Ma et al. CARDIOVASCULAR RESEARCH
- Serum Proprotein Convertase Subtilisin/Kexin Type 9 and Cell Surface Low-Density Lipoprotein Receptor
- (2013) Hagai Tavori et al. CIRCULATION
- Loss of Plasma Proprotein Convertase Subtilisin/Kexin 9 (PCSK9) After Lipoprotein Apheresis
- (2013) Hagai Tavori et al. CIRCULATION RESEARCH
- Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Can Mediate Degradation of the Low Density Lipoprotein Receptor-Related Protein 1 (LRP-1)
- (2013) Maryssa Canuel et al. PLoS One
- Elevated PCSK9 Levels in Untreated Patients With Heterozygous or Homozygous Familial Hypercholesterolemia and the Response to High‐Dose Statin Therapy
- (2013) Frederick Raal et al. Journal of the American Heart Association
- Gene Inactivation of Proprotein Convertase Subtilisin/Kexin Type 9 Reduces Atherosclerosis in Mice
- (2012) Maxime Denis et al. CIRCULATION
- Lack of a relationship between plasma PCSK9 concentrations and hepatic lipoprotein kinetics in obese people
- (2011) Shelby Sullivan et al. Translational Research
- Increased Secretion of Lipoproteins in Transgenic Mice Expressing Human D374Y PCSK9 Under Physiological Genetic Control
- (2010) Bronwen Herbert et al. ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY
- PCSK9 is not involved in the degradation of LDL receptors and BACE1 in the adult mouse brain
- (2010) Mali Liu et al. JOURNAL OF LIPID RESEARCH
- Proprotein Convertase Subtilisin Kexin Type 9 Null Mice Are Protected From Postprandial Triglyceridemia
- (2009) Cédric Le May et al. ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY
- Genetic and Metabolic Determinants of Plasma PCSK9 Levels
- (2009) Susan G. Lakoski et al. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
- A new method for measurement of total plasma PCSK9: clinical applications
- (2009) Geneviève Dubuc et al. JOURNAL OF LIPID RESEARCH
- Self-Association of Human PCSK9 Correlates with Its LDLR-Degrading Activity†
- (2008) Daping Fan et al. BIOCHEMISTRY
- Plasma PCSK9 Concentrations Correlate with LDL and Total Cholesterol in Diabetic Patients and Are Decreased by Fenofibrate Treatment
- (2008) G. Lambert et al. CLINICAL CHEMISTRY
- Regulation of ApoB Secretion by the Low Density Lipoprotein Receptor Requires Exit from the Endoplasmic Reticulum and Interaction with ApoE or ApoB
- (2008) Daniel A. Blasiole et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- Function and distribution of circulating human PCSK9 expressed extrahepatically in transgenic mice
- (2008) Yi Luo et al. JOURNAL OF LIPID RESEARCH
Find the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
SearchBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started